Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just had a catch up and chuckle at the positive and negative reviews on Boots, about Eroxon
It no longer seems to be a coincidence, that almost every 1 star review always refers to "money wasted" in their post?!?!
RE Jet's comment about LOM taking some profit and a nice business to be in, I feel that is just reward for the steadfast way they've backed FUM, even in the dark old days of P3 failure. In my book they can do no wrong. But there again I'm a fairly naive investor, just hoping to make a bit of money towards my trip to Fantasy Island! I can't see 81lucky's predictions all coming true though, I expect I'll sell after the FDA rocket. This share hasn't been great for my blood pressure, even though I'm up at the moment! GLA!
I bought half my holding at a good price of about 15p years ago. I bought quarter at about 70p after EU approval [massive mistake] and the rest somewhere between 30/40p. This share has been all over the place in the last few years sometimes for a reason, sometimes not. I think it’s just worn me out where my head says take the profit while you still can. Heart says if certain things happen this reaches £2 plus easily and I can retire. It’s not been an easy journey as anyone who has been here years will know.
"But FDA is never 100%"... still doesn't sound confident!
All we know It’s due Q2
I’m not selling but not buying. I’ve made no secret down the years I’m heavily invested here. But FDA is never 100% - if it was this would already be over £1.
Ah, so not that confident eh Tommy!!
I’m confident on that, but not so confident to add any more shares at this stage.
Does anyone know the current timescale for the FDA decision?
This share price will smash through 60p barrier and through the £1 barrier when FDA approval is given
would not mind some proper movement.... this 60p barrier has been a pain for quite some time now.... Already on a decent profit and will keep being patient until the take off.
With FDA approval knocking on the door hopefully we should see some significant movement
Following this thread, it appears to me that PI,s are focusing upon a quick turn profit. ( akin to 'stags' during privatization days). If this goes the Viagra route (which, signs, are it will...and then some), makes this an investment vehicle.
Whilst not getting ahead of myself, I see FUM entering the FTSE250, which will automatically bring on board investment funds, perpetuating it further towards the big one and hedge funds etc.
Depending upon Lombard's own investment strategy, when they get close to it, they could transfer their stake to any fund manger with longer term stratgey.
My view of FDA decision is that obviously an approval will catapult this to a different level, there will be SP turbulence in the short-term, if FDA decide to play 'silly buggers'. In the longer term, nobody's putting the genie back in the bottle. This will be available worldwide, including US. The question is, will the company driving it be FUM?
Jet, everyones gotta make cash, just ask the paperhands
Bruce......could you explain the relevance please as I'm unsure why having qualified staff in a pharmacy for an OTC product is an issue. Its exactly the opposite that Eroxon can be purchased without the need to consult the pharmacist hence why its marketed as OTC.
Boots is poorly run. On a trip from Italy 5 months ago there was no pha****** in the major Worthing store for 5 hours. Next door at Superdrug same situation.
In Italy all workers in pharmacies are fully quaified
The only thing stopping the share price from erupting is I would suggest Lombard selling at a very nice 500% plus profit, then I suspect they will activate their warrants at 40p and at some point sell those too for a 500% profit. What a lovely business to be in.
Encouragingly, as the launch of Eroxon builds in Europe, Futura expects to generate maiden commercial revenues this year.
“Given the lack of visibility with regards to either timing or quantum of these revenues, we haven’t yet factored them into our forecasts, but these, together with other potential sources of income mean that we are very comfortable that Futura is well funded to deliver without needing to turn to equity markets,” said Liberum in a note to clients.
“We leave our forecasts largely unchanged. The shares continue to trade at a discount to our estimate of fair value, and we see the FDA decision on US market authorisation in Q2 as an important catalyst to closing this.”
Just clicked on boots eroxon page and it flashed up 100+ have brought today and last sold 37 seconds ago. Then I compared it to a number seven day cream which is a top seller it said 87 sold today and last sold 30 minutes ago. It sometimes flashes how many people are looking at each product at the same time as you. It’s interesting and in my view gives us a good idea of how popular Eroxon is.
Ok, my turn to go into the huge out of town Boots store in Kingsteignton, Devon. There was a space for our product next to the Durex but none available. It was too busy to ask if they were selling welm or if they were due any more.
i was coming home on the tube last night, and after reading several adverts in the carriages ( not much else to do, if you do not have anything to read) i noticed quite a few health related adverts ,, products to solve particular health problems such a Menopause tablets, cosmetic surgery, health insurance, acne cream etc .....
It made me think that an eye catching advert for a gel, you can buy from Boots that makes you hard with no side effects would be perfect for both the day time commuters, also the younger night party crowd and possibly even general tourists from around the world who can buy and try while in UK.
Or even better, on one of the large digital display boards in Piccadilly, the ones just above the a massive Boots chemist Lol.
Anyway, can only assume (I know, never do that) this is selling very well. You can buy pack of 4 for £24.99, but a pack of 12 is £74.98. It might just be 1p more but I thought retailers were in the habit of rewarding you for buying more, not charging you.
Just for the sake of balance, there are organisations called Banks whose business model is to lend money. All cash raised with small caps does not have to be a dilutive equity raise and given that Eroxon is now selling and generating revenue I am sure that the management team will now be well received if they take their cash flow forecasts into their bankers if they need some short term assistance. After all, management are shareholders too and will want to protect their own assets as much as we do. Typical bulletin board rhetoric to suggest more equity raise particularly for those who want a cheaper entry eh?
Andy, are you referring to the Simply Wall Street article on Yahoo Finance?
They are of no importance at all. These articles about cash-burn are computer generated and don't make sense on FUM right now.
If you scroll to the About Us page of Simply Wall Street, you can read: "The team has developed a proprietary AI system to provide coverage on small and mid cap stocks that are often ignored, alongside hand written analysis on popular stocks."
So hooray, we investors know more than the AI-robots at the moment. Expected revenues are not priced in by the news-generating-robots, I suspect they are also still under the radar of the investment-bots untill FDA approval gets them into the news.. good times are coming!
Andy96: there's two aspects to the 'cash' question that needs to be considered.
Firstly, the Yahoo article by itself is 'correct' regarding the risk of cash burn-through and hence need to raise.
Secondly, yes FUM have stated that cash level extends into Eroxon launch.
But, the Yahoo article ignores anyy potential revenu while the FUm statementvgives no clue as to when they can expect any revenu.
So we as investors are left with a bit of a grey area as to whether FUM can gain sufficient revenu via an ongiong basis to staive off any cash raise.
We all hope that FUM will announce (sooner than later) when revenue is likely and how much and timescales.
Also a confirmation that they WON'T need to raise funds by other means.
On the bright side. I have no doubt revenue will trickle in to prevent any raise and future revenue will increase to push market value.
Hence my "Strong Buy" opinion.